1
|
Westhovens R. CT-P13 SC for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2021; 18:5-13. [PMID: 34842032 DOI: 10.1080/1744666x.2022.2012451] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
INTRODUCTION Management of Rheumatoid Arthritis (RA) has improved following the implementation of early intensive treat to target recommendations and the availability of different biologicals. Most experience is with TNF blockers, but challenges remain in the efficacy/safety balance, immunogenicity, and long-term drug survival as well as availability and affordability despite the introduction of biosimilars. AREA COVERED We provide an overview of the development of CT-P13 SC based on infliximab biosimilar CT-P13 IV. The one-year pivotal phase I/III trial in RA showed CT-P13 120 mg SC fixed dose to have favorable pharmacokinetics compared to CT-P13 IV classical weight adapted dosing, similar to lower anti-drug antibodies, similar safety and non-inferiority for efficacy at 6 months. EXPERT OPINION CT-P13 SC is an additional option in RA treatment and by extension for other inflammatory diseases as Inflammatory Bowel Disease. This new way of administration has the potential to improve long-term drug survival of infliximab, improve patient outcomes, and patient comfort.
Collapse
Affiliation(s)
- Rene Westhovens
- Skeletal Biology and Engineering Research Center, Department of Development and Regeneration KU Leuven, Rheumatologist UZ, Leuven, Belgium
| |
Collapse
|
2
|
Kawahito Y, Takakubo Y, Morinobu A, Matsubara N, Nagy O, Sugiyama E. Patient satisfaction, preferences, expectations, characteristics, and impact of suboptimal control of rheumatoid arthritis: A subgroup analysis of Japanese patients from a large international cohort study (SENSE). PLoS One 2021; 16:e0259389. [PMID: 34780502 PMCID: PMC8592402 DOI: 10.1371/journal.pone.0259389] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2021] [Accepted: 10/18/2021] [Indexed: 11/17/2022] Open
Abstract
OBJECTIVE To evaluate treatment satisfaction, disease outcomes, and perspectives of patients with poorly controlled rheumatoid arthritis (RA) treated with conventional synthetic, targeted synthetic, or biologic disease-modifying antirheumatic drugs (DMARDs), we conducted a subgroup (post hoc) analysis of Japanese patients participating in the SENSE study. METHODS Data for Japanese patients (n/N = 118/1629) from the global, multicenter, cross-sectional, observational SENSE study were analyzed. The primary endpoint was the global satisfaction subscore assessed using the Treatment Satisfaction Questionnaire for Medication (TSQM) version 1.4. Other patient-reported outcomes included self-reported RA medication adherence and Work Productivity and Activity Impairment-RA. Patient perspectives included patients' expectations and preference of pharmacologic treatment. RESULTS Median (range) age and RA disease duration were 67.0 (18.0-87.0) years and 8 (0.0-54) years, respectively; 81.4% of patients were female. Mean (SD) TSQM global satisfaction subscore was 56.8 (17.5), and only 5.9% of patients reported good satisfaction with treatment (TSQM global ≥80). Mean (SD) self-reported treatment adherence using VAS was high (93.5% [13.8%]). Mean (SD) total work productivity impairment was 45.6% (32.0%); presenteeism contributed toward more total work productivity impairment (43.9% [30.4%]) than absenteeism (8.3% [24.4%]). Patients expected improvement in all parameters from their treatment, especially improvement in joint symptoms. Most patients (80.7%) preferred oral medication and 18.7% preferred monotherapy. Patient acceptability of potentially manageable side effects was high (7.5%-34.0%). Although most patients (81.3%) found combination therapy acceptable, 43.2% were receiving DMARD monotherapy. CONCLUSION Although most Japanese patients with RA with moderate-to-high disease activity were dissatisfied with their current DMARD treatment, high treatment adherence, high acceptability of combination therapy, high acceptability of manageable potential side effects, and preference for oral medication were reported. Data support the development of a more individualized and patient-centric approach for RA treatment.
Collapse
Affiliation(s)
- Yutaka Kawahito
- Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
| | - Yuya Takakubo
- Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan
| | - Akio Morinobu
- Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Naoko Matsubara
- Study Design and Data Science Team Evidence Solution Group Medical, AbbVie GK, Tokyo, Japan
| | - Orsolya Nagy
- Global Medical Affairs, AbbVie, Chicago, Illinois, United States of America
| | - Eiji Sugiyama
- Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
| |
Collapse
|
3
|
Dey D, Sciascia S, Pons-Estel GJ, Ding H, Shen N. Health Disparities in Rheumatic Diseases: Understanding Global Challenges in Africa, Europe, Latin America, and Asia and Proposing Strategies for Improvement. Rheum Dis Clin North Am 2021; 47:119-132. [PMID: 34042051 DOI: 10.1016/j.rdc.2020.09.009] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Rheumatic diseases reach across continents with some similarities as well as unique challenges. The intersection between genetic factors, environmental exposures and socioeconomic factors, as well as challenges, with delays in access to subspecialty care and medications, manifest in different ways. By understanding both the challenges and successes in different countries, while also recognizing the significant diversity both within and across continents, unified strategies to improve rheumatic disease outcomes and decrease disparities among the most vulnerable groups can be developed and disseminated.
Collapse
Affiliation(s)
- Dzifa Dey
- Rheumatology Unit, Department of Medicine and Therapeutics, Korlebu Teaching Hospital, University of Ghana Medical School, College of Health Sciences, PO Box 4236, Korle-Bu, Accra, Ghana.
| | - Savino Sciascia
- Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d'Aosta Network for Rare Diseases, and SCDU Nephrology and Dialysis, Department of Clinical and Biological Sciences, S. Giovanni Bosco Hospital and University of Turin, Piazza del Donatore di Sangue 3, Turin 10154, Italy
| | | | - Huihua Ding
- Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Nan Shen
- Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| |
Collapse
|
4
|
Fernández-Ávila DG, Patino-Hernandez D, Kowalskii S, Vargas-Caselles A, Sapag AM, Cachafeiro-Vilar A, Meléndez-Muñoz L, Santiago-Pastelín C, Graf C, Rossetto C, Palleiro D, Trincado D, Fernández-Ávila D, Arrieta D, Reyes G, Then Baez J, Ugarte-Gil MF, Cardiel M, Colman N, Chávez N, Burgos PI, Montúfar R, Sandino S, Fuentes-Silva Y, Soriano ER. Current status of the rheumatologists' workforce in Latin America: a PANLAR collaborative study. Clin Rheumatol 2021; 40:2913-2920. [PMID: 33449230 DOI: 10.1007/s10067-020-05555-w] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Revised: 12/06/2020] [Accepted: 12/16/2020] [Indexed: 12/11/2022]
Abstract
INTRODUCTION Studies conducted by various scientific societies have shown that the demand for specialized rheumatology care is greater than the projected growth of the workforce. Our research aims to assess the current status of the rheumatology workforce in Latin America. METHOD This is a descriptive, cross-sectional study. A survey was created on the RedCap platform. Data were analyzed with STATA 15® Software. We present descriptive analyses. The rate of inhabitants per rheumatologist was calculated using the number of rheumatologists practicing in each country and the inhabitants for year 2020. RESULTS Our sample was composed by 19 PANLAR member countries in Latin America. Latin America has one rheumatologist per 106,838 inhabitants. The highest rate of rheumatologist per inhabitants was found in Uruguay (1 per 27,426 inhabitants), and the lowest was found in Nicaragua (1 per 640,648 inhabitants). Mean age was 51.59 (SD12.70), ranging between 28 and 96 years of age. Mean monthly compensation was USD $2382.6 (SD$1462.5). The country with lowest salary was Venezuela ($197), whereas the highest was Costa Rica ($4500). CONCLUSIONS There is a high variability in rheumatologists' workforce characteristics in Latin America. These results could lead to policies aiming to increase the availability and income of rheumatologists, in order to increase opportunity and quality of care of patients living with rheumatic diseases. Key Points • The rheumatologists' workforce varies significantly among Latin American countries. • The supply of rheumatologists is insufficient for meeting the increasing need for specialists in this field.
Collapse
Affiliation(s)
- Daniel Gerardo Fernández-Ávila
- Unidad de Reumatología, Hospital Universitario San Ignacio - Facultad de Medicina, Pontificia Universidad Javeriana, Unidad de Investigación PANLAR, Cra 7 # 40-62, Bogotá, Colombia.
| | - Daniela Patino-Hernandez
- Departamento de Medicina Interna, Hospital Universitario San Ignacio - Pontificia Universidad Javeriana, Bogotá, Colombia
| | - Sergio Kowalskii
- Universidade Federal do Paraná, Unidad de Inivestigación PANLAR, Paraná, Brazil
| | | | | | | | | | | | - Cesar Graf
- Sociedad Argentina de Reumatología, Buenos Aires, Argentina
| | | | - Daniel Palleiro
- Instituto Nacional de Reumatología del Uruguay - Universidad de la República, Montevideo, Uruguay
| | - Daniela Trincado
- Departamento de Inmunología Clínica y Reumatología, Pontificia Universidad Católica de Chile, Santiago de Chile, Chile
| | | | - Dina Arrieta
- Hospital México, Caja Costarricense del Seguro Social, San José de Costa Rica, Costa Rica
| | - Gil Reyes
- Universidad de Ciencias Médicas de La Habana, La Habana, Cuba
| | | | - Manuel F Ugarte-Gil
- Universidad Científica del Sur - Hospital Guillermo Almenara Irigoyen, Lima, Peru
| | - Mario Cardiel
- Centro de Investigación Clínica de Morelia, Morelia, Mexico
| | - Nelly Colman
- Hospital de Clínicas - Universidad Nacional de Asunción, Asunción, Paraguay
| | - Nilmo Chávez
- Universidad San Carlos de Guatemala - Instituto Guatemalteco de Seguridad Social, Guatemala City, Guatemala
| | - Paula I Burgos
- Pontificia Universidad Católica de Chile, Dto de Inmunologia Clínica y Reumatología, Santiago de Chile, Chile
| | - Ruben Montúfar
- Consultorio de Especialidades del Instituto Salvadoreño del Seguro Social, San Salvador, El Salvador
| | | | | | | |
Collapse
|
5
|
Oliver S, Tam LS, Suet-Kei Kwok G, Fusama M, Nakahara H, Zhang CY, Yamamoto K, Furtner D. The Asia-Pacific Initiative for Rheumatology Nurse Education: Current gaps, programme development and future outlook. Musculoskeletal Care 2020; 18:397-403. [PMID: 32302046 DOI: 10.1002/msc.1473] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Accepted: 04/04/2020] [Indexed: 12/21/2022]
Affiliation(s)
- Susan Oliver
- Rheumatology Nurse Consultant, Susan Oliver Associates, Barnstaple, Devon, UK
| | - Lai-Shan Tam
- Department of Medicine & Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong
| | | | - Mie Fusama
- School of Nursing, Takarazuka University, Osaka, Japan
| | - Hideko Nakahara
- Faculty of Health Science, Osaka Yukioka College of Health Sciences, Osaka, Japan
| | - Chun-Yan Zhang
- Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China
| | - Kazuhiko Yamamoto
- Center for Integration Medical Sciences, RIKEN Yokohama Institute, Yokohama, Japan
| | - Daniel Furtner
- Janssen, a Division of Johnson & Johnson Private Limited, Singapore
| |
Collapse
|
6
|
Sandhu VK, Hojjati M, Blanco I. Healthcare disparities in rheumatology: the role of education at a global level. Clin Rheumatol 2019; 39:659-666. [PMID: 31602534 DOI: 10.1007/s10067-019-04777-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Revised: 09/05/2019] [Accepted: 09/09/2019] [Indexed: 01/12/2023]
Abstract
All fields of medicine are victim to health inequity worldwide, including rheumatology. While the health system is a key proponent to health access for all, other social determinants of health also impact world health. We describe herein the current state of global healthcare disparities in rheumatology and attempts at optimizing graduate medical education and resources for optimized healthcare, international research collaborations and a future of universal health equity. We performed a comprehensive search through Pubmed using the following keywords: healthcare disparities, medical education, access to care, community health.Key Points• Healthcare disparities are ubiquitous globally, including the field of rheumatology.• The heterogeneity of global healthcare disparities emphasizes the importance of addressing unmet needs at a regional level.• A standardized approach to incorporating healthcare disparities education in the medical field is lacking. Intervening at this level provides a foundation of increasing provider awareness of regional healthcare disparities so as to establish a framework of addressing such disparities in a culturally competent manner.
Collapse
Affiliation(s)
- Vaneet Kaur Sandhu
- Division of Rheumatology, Department of Medicine, Loma Linda University, 11234 Anderson Street, MC-1516, Loma Linda, CA, 92354, USA.
| | - Mehrnaz Hojjati
- Division of Rheumatology, Department of Medicine, Loma Linda University, 11234 Anderson Street, MC-1516, Loma Linda, CA, 92354, USA
| | - Irene Blanco
- Division of Rheumatology, Department of Medicine, Albert Einstein College of Medicine, 1300 Morris Park Ave, Bronx, NY, 10461, USA
| |
Collapse
|